Clinical Trial Update: A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation [Phase 3]

View source ↗

Summary

Biogen initiated a Phase 3 trial of tofersen (BIIB067) in presymptomatic adults with a confirmed SOD1 mutation for amyotrophic lateral sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• Tofersen (tofersen)

Snippet

Sponsor: Biogen | Conditions: Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation | Phase 3 | Status: ACTIVE_NOT_RECRUITING